Tools for Cell Line Identification (R43/R44) | Apply Online

FAQs: NIH "Tools for Cell Line Identification (R43/R44)" (PA-16-186)

What is this funding opportunity?

This is an NIH Small Business Innovation Research (SBIR) funding opportunity titled "Tools for Cell Line Identification (R43/R44)" under FOA number PA-16-186. It supports commercialization-oriented research and development to improve how researchers authenticate cell lines used in biomedical research.

What problem is NIH trying to solve with this FOA?

The FOA targets the long-standing issue of misidentified and contaminated cell lines. Cell cultures can be cross-contaminated or replaced by faster-growing foreign cells, leading labs to unknowingly run experiments on the wrong cells. This can undermine results, waste time and money, and contribute to findings that are difficult to reproduce.

Why is cell line authentication considered important here?

Cell lines are foundational tools in basic biology, disease modeling, and drug discovery. When the identity of a cell line is wrong, downstream conclusions can be unreliable. The FOA frames routine authentication as a research rigor and reproducibility issue, where better tools could make verification a normal, repeatable quality control (QC) step.

Why do many labs not verify cell line identity routinely?

Even though routine verification is a best practice, many labs do not do it consistently because current options can be too expensive, too slow, or operationally inconvenient for real-world workflows.

What is the primary goal of the program?

The primary goal is to push the market toward routine, practical cell line authentication by funding small businesses to improve existing methods and/or create new technologies that are accurate, reliable, and affordable, with reduced burden in day-to-day laboratory workflows.

What kinds of solutions does NIH want to support?

The FOA emphasizes tools and technologies that make it easier for researchers to confirm the identity of a cell line and, where relevant, the sex of the cells being studied. The intent is to remove practical barriers that prevent frequent verification.

Does the FOA focus only on cell line identity, or also other attributes?

Based on the provided description, the FOA emphasizes confirming both cell line identity and, where relevant, the sex of the cells being studied.

What would make a proposed tool more attractive under this FOA?

Proposals that reduce real-world burden in lab workflows align strongly with the stated emphasis. Examples of desirable improvements mentioned include faster turnaround, simpler sample preparation, lower per-sample cost, better automation, clearer interpretation of results, and integration into standard QC pipelines.

Is this opportunity focused on commercialization?

Yes. The mechanism is SBIR (R43/R44), and the description highlights commercialization-oriented R&D that can lead to broader adoption of authentication products or services.

What award mechanism does this FOA use?

The FOA uses the NIH SBIR Phase I/Phase II mechanisms R43/R44, allowing applicants to propose early feasibility and prototyping work (Phase I) as well as later-stage development and validation (Phase II) to support product or service readiness for adoption.

Can applicants propose both Phase I and Phase II-type work?

The opportunity is described as supporting Phase I/Phase II (R43/R44), which indicates support across early feasibility/prototyping through later-stage development and validation that positions a technology for broader use.

Does the FOA allow larger-than-typical SBIR budgets or longer project periods?

Yes. The announcement explicitly encourages applications involving complex technology development that may require budgets and project periods beyond typical SBIR expectations, reflecting the engineering, assay development, software, or validation needs of robust authentication platforms.

Are multi-PD/PI applications allowed?

Yes. The FOA explicitly welcomes multi-PD/PI projects.

Are academic-industry partnerships encouraged?

Yes. The announcement specifically notes that academic-industry partnerships are encouraged, which aligns with the translational nature of developing tools that must perform reliably in diverse research settings.

Who is eligible to apply?

Eligibility is limited to small businesses, consistent with the SBIR focus of the opportunity.

Which agency sponsors this opportunity?

The sponsoring agency is the U.S. Department of Health and Human Services (HHS), National Institutes of Health (NIH).

What type of grant is this categorized as?

It is categorized as a discretionary grant.

Is this opportunity limited to one NIH institute or program area?

The opportunity spans multiple NIH program areas, reflected by multiple listed CFDA numbers, signaling broad relevance across institutes and research domains that rely on cell culture.

What are the key dates mentioned for this FOA?

The posted and created date is April 15, 2016, and the closing date is April 5, 2019.

Does the provided summary include an award ceiling or the expected number of awards?

No. The provided summary data does not specify an award ceiling or the expected number of awards.

What outcomes does NIH expect these funded projects to support?

The intended outcome is broader adoption of practical authentication approaches that make it normal to verify cell identity and sex (when relevant). This is meant to improve research rigor, reproducibility, and confidence in cell-based findings while reducing wasted funding and time caused by cell line problems.

How does this FOA connect to research reproducibility?

Misidentified or contaminated cell lines can lead to experiments being conducted on the wrong biological material, which can invalidate conclusions and contribute to results that are difficult to reproduce. By making authentication easier and more routine, the FOA aims to reduce this source of irreproducibility.

Is the FOA aimed at improving existing methods, developing new methods, or both?

Both. The FOA is designed to support small businesses that can improve existing methods and/or create new technologies for accurate, reliable, and affordable cell line authentication.